Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Ells

Gastroenterology East Setauket, NY Medical Doctor

NPI 1336174143 CMS profile 332350

3 Technology Dr, East Setauket, NY 11733

Open in the dashboard

General payments

$81,282

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Ells of East Setauket, NY is reported in the CMS Open Payments database as having received $81,282 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,147 72
2024 General $10,990 49
2023 General $13,651 61
2022 General $14,912 45
2021 General $7,855 46
2020 General $6,585 13
2019 General $17,142 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Ells
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Peter Ells were reported at $10,147. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Peter Ells Gastroenterology median Middle half National median
2019 $17,142 $417 $126–$1,100 $163
2020 $6,585 $224 $74–$624 $114
2021 $7,855 $352 $106–$1,054 $132
2022 $14,912 $448 $129–$1,270 $149
2023 $13,651 $533 $150–$1,390 $160
2024 $10,990 $605 $160–$1,606 $164
2025 $10,147 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $72,935 124 payments
  2. Intercept Pharmaceuticals, Inc. $4,291 18 payments
  3. AbbVie, Inc. $1,586 87 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $679 32 payments
  5. Janssen Biotech, Inc. $361 11 payments
  6. Madrigal Pharmaceuticals $235 4 payments
  7. Regeneron Healthcare Solutions, Inc. $207 6 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $177 9 payments
  9. CONMED Corporation $130 1 payment
  10. Ardelyx, Inc. $125 5 payments
  11. Other $557 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,220 28 payments
  2. Travel and Lodging $9,737 28 payments
  3. Food and Beverage $7,343 254 payments
  4. Consulting Fee $4,660 2 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,200 1 payment
  6. Honoraria $1,000 2 payments
  7. Education $122 3 payments
Products named General payments · program years 2019–2025
  1. Epclusa $51,810 61 payments
  2. Vemlidy $5,434 7 payments
  3. OCALIVA $4,072 9 payments
  4. RINVOQ $969 44 payments
  5. XIFAXAN $679 32 payments
  6. HUMIRA $384 26 payments
  7. TREMFYA $345 10 payments
  8. SKYRIZI Immunology $335 16 payments
  9. REZDIFFRA $235 4 payments
  10. SKYRIZI Immunology $226 12 payments
  11. Other $1,762 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

401

Median for Gastroenterology: 569

Drug cost

$200,775

Median for Gastroenterology: $104,976

Branded share of claims

16.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 49 $165,892
Linzess Linaclotide Brand 17 $12,166
Ursodiol Generic 35 $10,551
Entecavir Generic 43 $6,642
Azathioprine Generic 39 $1,439
Lactulose Generic 26 $1,041
Omeprazole Generic 82 $904
Spironolactone Generic 28 $834
Nadolol Generic 12 $584
Pantoprazole Sodium Generic 28 $402

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$18,770

Medicare's payments for the services billed

Medicare patients

214

Average age 68

Services billed

336

118 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 36%
Ischemic heart disease 32%
Chronic kidney disease 29%
Depression 29%
Heart failure 22%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epclusa
  • Gilead Sciences, Inc. $3,184
$3,184 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $187
$187 49 —
RINVOQ
  • AbbVie, Inc. $173
$173 — —
SKYRIZI
  • AbbVie, Inc. $139
$139 — —
DUPIXENT
  • GENZYME CORPORATION $66
  • Regeneron Healthcare Solutions, Inc. $14
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record